Market closed

Clene/$CLNN

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Clene

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).

Ticker

$CLNN

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Salt Lake City, United States

Employees

Website

clene.com

Clene Metrics

BasicAdvanced

$39M

-

-$5.58

0.32 -

Price and volume

Market cap

$39M

Beta

0.32

52-week high

$11.00

52-week low

$3.82

Average daily volume

94K

Financial strength

Current ratio

0.827

Quick ratio

0.615

Long term debt to equity

-273.309

Total debt to equity

-554.691

Interest coverage (TTM)

-7.24%

Management effectiveness

Return on assets (TTM)

-46.69%

Return on equity (TTM)

-416.92%

Valuation

Price to revenue (TTM)

75.947

Price to book

-8.23

Price to tangible book (TTM)

-8.23

Price to free cash flow (TTM)

-1.35

Growth

Revenue change (TTM)

-41.37%

Earnings per share change (TTM)

-37.48%

3-year revenue growth (CAGR)

-8.69%

3-year earnings per share growth (CAGR)

1.68%

What the Analysts think about Clene

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Clene stock.

Clene Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Clene Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Clene News

AllArticlesVideos

FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS

GlobeNewsWire·1 month ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CLNN

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Clene stock?

Clene (CLNN) has a market cap of $39M as of January 15, 2025.

What is the P/E ratio for Clene stock?

The price to earnings (P/E) ratio for Clene (CLNN) stock is 0 as of January 15, 2025.

Does Clene stock pay dividends?

No, Clene (CLNN) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Clene dividend payment date?

Clene (CLNN) stock does not pay dividends to its shareholders.

What is the beta indicator for Clene?

Clene (CLNN) has a beta rating of 0.32. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.